BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37866161)

  • 21. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
    Vasudevan KM; Barbie DA; Davies MA; Rabinovsky R; McNear CJ; Kim JJ; Hennessy BT; Tseng H; Pochanard P; Kim SY; Dunn IF; Schinzel AC; Sandy P; Hoersch S; Sheng Q; Gupta PB; Boehm JS; Reiling JH; Silver S; Lu Y; Stemke-Hale K; Dutta B; Joy C; Sahin AA; Gonzalez-Angulo AM; Lluch A; Rameh LE; Jacks T; Root DE; Lander ES; Mills GB; Hahn WC; Sellers WR; Garraway LA
    Cancer Cell; 2009 Jul; 16(1):21-32. PubMed ID: 19573809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma.
    Liu M; Chen L; Chan TH; Wang J; Li Y; Li Y; Zeng TT; Yuan YF; Guan XY
    Hepatology; 2012 Jun; 55(6):1754-65. PubMed ID: 22262416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
    Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
    Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
    Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
    J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
    Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel role for SGK3 in glucose homeostasis revealed in SGK3/Akt2 double-null mice.
    Yao LJ; McCormick JA; Wang J; Yang KY; Kidwai A; Colussi GL; Boini KM; Birnbaum MJ; Lang F; German MS; Pearce D
    Mol Endocrinol; 2011 Dec; 25(12):2106-18. PubMed ID: 21980074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
    Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
    Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways.
    Kong X; Liu F; Gao J
    Oncotarget; 2016 Oct; 7(40):66051-66060. PubMed ID: 27602769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
    Krishnamurthy S; Yoda H; Hiraoka K; Inoue T; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Sci; 2021 Mar; 112(3):1141-1149. PubMed ID: 33377228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
    Wang Y; Zhou D; Chen S
    Mol Endocrinol; 2014 Jun; 28(6):935-48. PubMed ID: 24739041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the
    Jiang W; Wu Y; He T; Zhu H; Ke G; Xiang L; Yang H
    Mol Cancer Ther; 2020 Feb; 19(2):337-347. PubMed ID: 31666350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SGK3-triggered ubiquitin-proteasome degradation of podocalyxin (PC) and ezrin in podocytes was associated with the stability of the PC/ezrin complex.
    Yuan YP; Zhao H; Peng LQ; Li ZF; Liu S; Yuan CY; Mwamunyi MJ; Pearce D; Yao LJ
    Cell Death Dis; 2018 Nov; 9(11):1114. PubMed ID: 30385740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human umbilical cord-derived mesenchymal stem cell transplantation supplemented with curcumin improves the outcomes of ischemic stroke via AKT/GSK-3β/β-TrCP/Nrf2 axis.
    Li Y; Huang J; Wang J; Xia S; Ran H; Gao L; Feng C; Gui L; Zhou Z; Yuan J
    J Neuroinflammation; 2023 Feb; 20(1):49. PubMed ID: 36829224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.
    Chi MN; Guo ST; Wilmott JS; Guo XY; Yan XG; Wang CY; Liu XY; Jin L; Tseng HY; Liu T; Croft A; Hondermarck H; Scolyer RA; Jiang CC; Zhang XD
    Oncotarget; 2015 Nov; 6(37):39891-907. PubMed ID: 26573229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum and Glucocorticoid-Inducible Kinase 3/Nedd4-2 Signaling Pathway Participates in Podocyte Injury by Regulating the Stability of Nephrin.
    Dong QQ; Li ZF; Zhang H; Shu HP; Tu YC; Liao QQ; Yao LJ
    Front Physiol; 2021; 12():810473. PubMed ID: 35126185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
    Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
    J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
    Liu JJ; Ho JY; Lee HW; Baik MW; Kim O; Choi YJ; Hur SY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.